E-LIB Suche - Ergebnisse für: Banerjee, Subhashis

1

Efficacy of Deucravacitinib, an Oral, Selective, Allosteric..:

Blauvelt, Andrew ; Sofen, Howard ; Lambert, Jo...
SKIN The Journal of Cutaneous Medicine. 8 (2024) 4 - p. s405 , 2024

Link: https://doi.org/10.25251..

2

Deucravacitinib Improves Patient-Reported Outcomes in Patie..:

Armstrong, April W. ; Augustin, Matthias ; Beaumont, Jennifer L....
Dermatology and Therapy. , 2024

Link: https://doi.org/10.1007/..

3

Traceable mixnets:

Agrawal, Prashant ; Nakarmi, Abhinav ; Jhanwar, Mahabir Prasad..
Proceedings on Privacy Enhancing Technologies. 2024 (2024) 2 - p. 235-275 , 2024

Link: https://doi.org/10.56553..

4

Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Bi..:

FitzGerald, Oliver ; Gladman, Dafna D. ; Mease, Philip J....
Arthritis & Rheumatology. , 2024

Link: https://doi.org/10.1002/..

5

Deucravacitinib onset of action and maintenance of response..:

Korman, Neil J. ; Warren, Richard B. ; Bagel, Jerry...
Journal of Dermatological Treatment. 35 (2024) 1 - p. , 2024

Link: https://doi.org/10.1080/..

6

Deucravacitinib Long-Term Efficacy in Week 16 Placebo Cross..:

Lebwohl, Mark ; Warren, Richard B. ; Imafuku, Shinichi...
SKIN The Journal of Cutaneous Medicine. 8 (2024) 2 - p. s365 , 2024

Link: https://doi.org/10.25251..

7

Deucravacitinib in moderate‐to‐severe plaque psoriasis: Poo..:

Strober, Bruce ; Blauvelt, Andrew ; Warren, Richard B....
Journal of the European Academy of Dermatology and Venereology. 38 (2024) 8 - p. 1543-1554 , 2024

Link: https://doi.org/10.1111/..

8

Deucravacitinib, a selective, allosteric tyrosine kinase 2 ..:

Blauvelt, Andrew ; Rich, Phoebe ; Sofen, Howard...
Journal of the American Academy of Dermatology. 90 (2024) 4 - p. 775-782 , 2024

Link: https://doi.org/10.1016/..

9

Plain Language Summary of the PAISLEY study: deucravacitini..:

Morand, Eric F. ; Pike, Marilyn ; Merrill, J...
Expert Opinion on Investigational Drugs. 33 (2024) 5 - p. 431-440 , 2024

Link: https://doi.org/10.1080/..

10

Deucravacitinib in Plaque Psoriasis: 4-Year Safety and Effi..:

Armstrong, April W. ; Lebwohl, Mark ; Warren, Richard B....
SKIN The Journal of Cutaneous Medicine. 8 (2024) 4 - p. s406 , 2024

Link: https://doi.org/10.25251..

11

Deucravacitinib in Plaque Psoriasis: Maintenance of Respons..:

Strober, Bruce ; Imafuku, Shinichi ; Paul, Carle...
SKIN The Journal of Cutaneous Medicine. 8 (2024) 4 - p. s407 , 2024

Link: https://doi.org/10.25251..

12

Biochemical, Biomarker, and Behavioral Characterization of ..:

Smith, Denise M. ; Aggarwal, Geetika ; Niehoff, Michael L....
Molecular Neurobiology. , 2024

Link: https://doi.org/10.1007/..

13

Deucravacitinib Long-Term Efficacy Through 4 years in Week ..:

Lebwohl, Mark ; Warren, Richard B. ; Imafuku, Shinichi...
SKIN The Journal of Cutaneous Medicine. 8 (2024) 4 - p. s408 , 2024

Link: https://doi.org/10.25251..

14

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Ki..:

Alexis, Andrew F. ; Merola, Joseph F. ; Zhong, Yichen...
SKIN The Journal of Cutaneous Medicine. 8 (2024) 2 - p. s358 , 2024

Link: https://doi.org/10.25251..

15

Impact of Oral, Selective, Allosteric Tyrosine Kinase 2 Inh..:

Gottlieb, Alice B. ; Armstrong, April W. ; Merola, Joseph F....
SKIN The Journal of Cutaneous Medicine. 8 (2024) 2 - p. s383 , 2024

Link: https://doi.org/10.25251..